Cargando…

Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout

AIMS: To investigate and characterise the pharmacokinetics of febuxostat and the effect of the covariates of renal function and body size descriptors on the pharmacokinetics of the drug. METHODS: Blood samples (n = 239) were collected using sparse and rich sampling strategies from healthy (n = 9) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamel, Bishoy, Abuhelwa, Ahmad Y., Foster, David, Duong, Janna K., Graham, Garry G., Williams, Kenneth M., Pile, Kevin D., Day, Richard O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796681/ https://www.ncbi.nlm.nih.gov/pubmed/35849446 http://dx.doi.org/10.1111/bcp.15462

Ejemplares similares

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
por: ZHANG, MEI, et al.
Publicado: (2014)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Effects of Febuxostat in Early Gout: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
por: Zhang, Fengchun, et al.
Publicado: (2019)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
por: Lee, Joondon, et al.
Publicado: (2023)

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
por: van Leeuwen, Kevin D. B., et al.
Publicado: (2019)

Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
por: Frassetto, Lynda Ann, et al.
Publicado: (2016)

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat
por: Sheer, Richard, et al.
Publicado: (2017)

Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis
por: Zhang, Zheng, et al.
Publicado: (2020)

The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout
por: Huang, Yuan-Yuan, et al.
Publicado: (2020)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
por: Zhang, Peiyu, et al.
Publicado: (2022)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study
por: Oh, Yoon-Jeong, et al.
Publicado: (2020)

The Clinical Effects of Febuxostat Alone or Combined with Arthroscopic Surgery for Gout: A Single-Center Retrospective Study
por: Gong, Zhen, et al.
Publicado: (2021)

Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial
por: Jia, Ertao, et al.
Publicado: (2021)

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
por: Gao, Linggen, et al.
Publicado: (2022)

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study
por: Saag, Kenneth G., et al.
Publicado: (2018)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
por: Gunawardhana, Lhanoo, et al.
Publicado: (2018)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice
por: Yu, Jeong-Eun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3av0pe9okjd04hn51o6r1g6aqs